Product Description
Novel small molecule kinase inhibitor that blocks tumorigenic wnt signalling. (Sourced from: https://www.apollotx.com/pipeline/)
Mechanisms of Action: Wnt Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Apollo Therapeutics Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for APL-5125](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Adenocarcinoma|Appendiceal Cancer|Cholangiocarcinoma|Colorectal Cancer|Endometrial Cancer|Gastrointestinal Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AP10CP01 | P2 |
Recruiting |
Gastrointestinal Cancer|Colorectal Cancer|Pancreatic Cancer|Adenocarcinoma|Triple Negative Breast Cancer|Ovarian Cancer|Appendiceal Cancer|Cholangiocarcinoma|Prostate Cancer|Endometrial Cancer |
2027-04-01 |